Biohaven's Revenue Path: SCA And Obesity Therapies [Seeking Alpha]
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Seeking Alpha
Myriam Alvarez 1.94K Follower s Follow Play 14min Summary Biohaven's pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor function improvements and favorable safety in Phase 3 trials. Despite a $250 million equity raise, BHVN's cash burn of $141.9 million per quarter poses financial sustainability risks, making commercialization critical. Therefore, BHVN's positive clinical progress, high cash burn, and frequent equity raises make it a speculative buy. syahrir maulana Biohaven Ltd. ( NYSE: BHVN ) is a clinical-stage biopharmaceutical company advancing its diversified immunology, neuroscience, oncology, and metabolic health pipeline. Sin
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.MarketBeat
- Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates [Yahoo! Finance]Yahoo! Finance
- Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program UpdatesPR Newswire
- Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
BHVN
Earnings
- 11/12/24 - Miss
BHVN
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 8-K
- 11/12/24 - Form 10-Q
- BHVN's page on the SEC website